Chemomab Therapeutics Ltd. Net Income Loss

• Chemomab Therapeutics Ltd. showed an increase of +35.5% in Net Income Loss from 2024 to 2025.
• This data is from Chemomab Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Chemomab Therapeutics Ltd.'s Net Income Loss has grown by 34.8%.
• Historical annual values: Fiscal year 2025: -$9.00 million | Fiscal year 2024: -$13.95 million | Fiscal year 2023: -$24.22 million | Fiscal year 2022: -$27.65 million | Fiscal year 2021: -$12.48 million | Fiscal year 2020: -$5.95 million | Fiscal year 2019: -$27.12 million | Fiscal year 2018: -$13.80 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026